GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
The Coinbase CEO-backed longevity company will advance its epigenetic reprogramming mRNA medicine into Phase I trials for fatty …
The Alphabet-backed spinout of DeepMind’s AlphaFold programme has raised the largest private financing round in AI drug discovery …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to …
The British pharma giant’s third major deal of 2026 secures two FDA Breakthrough Therapy-designated kinase inhibitors and a …
Led by Founders Fund and Thrive Capital, the round reflects sustained institutional conviction in cellular rejuvenation biology as …
The stealth-mode startup emerges with a pipeline targeting focal epilepsy, schizophrenia, tinnitus, and reversible encephalopathy — all acquired …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
FORECAST-2 trial pioneers the use of tumor organoids for personalized treatment selection in bowel cancer, aiming to revolutionize …
Already a subscriber? Log in